Clinical trials
catalyst calendar across sponsors →Studies where IMRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional
Held by 8 tracked-famous managers (MARSHALL WACE, LLP, CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, D. E. Shaw & Co., Inc., +3 more) · FINRA short interest 20.4 days to cover (settled 2026-07-31) · insider 90d: 2 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaNCT07562152Overall SurvivalRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Atebimetinib, GnP, mGnP | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma | 510 | Jun 2028 | ≤ 681 d | 2026-08-14 |
| A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsNCT05585320Phase 1: Adverse EventsNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + dabrafenib (Treatment Group D), IMM-1-104 + pembrolizumab (Treatment Group E) | Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC) | 209 | Jun 2026 | — | 2025-09-02 |
| A Study of IMM-6-415 in RAS/RAF Mutant Solid TumorsNCT06208124Phase 1/2a: Adverse EventsOpen-label · Treatment | Phase 1/2 | Completed | Drug: IMM-6-415 | Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma, Non-small Cell Lung Cancer, Malignant Melanoma (Cutaneous) | 30 | 2025-04-30actual | — | 2025-05-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19